Ivan Cruz-Chamorro

Dr. Ivan Cruz-Chamorro

Facultad deEnfermería, Universidad de Castilla-La Mancha, Albacete, Castille-La Mancha, Spain
+4
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
NÁNuria Álvarez-Sánchez
Nuria Álvarez-Sánchez
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro
ALAntonio López-González
Antonio López-González
JUJosé C. Utrilla
José C. Utrilla
JFJosé M. Fernández-Santos
José M. Fernández-Santos
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico

9 August 2017 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
NÁNuria Álvarez-Sánchez
Nuria Álvarez-Sánchez
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro
MDMaría Díaz‐Sánchez
María Díaz‐Sánchez
HSHelia Sarmiento‐Soto
Helia Sarmiento‐Soto
PMPablo Medrano‐Campillo
Pablo Medrano‐Campillo
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico

9 June 2022 in Trends in Food Science & Technology
Verified
Journal Article
Open access
Guillermo Santos-SánchezGuillermo Santos-Sánchez
Guillermo Santos-Sánchez
AÁAna Isabel Álvarez-López
Ana Isabel Álvarez-López
EPEduardo Ponce-España
Eduardo Ponce-España
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico
CBCarlotta Bollati
Carlotta Bollati
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro

24 December 2014 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
ALAntonio López‐González
Antonio López‐González
NÁNuria Álvarez-Sánchez
Nuria Álvarez-Sánchez
Patricia J. LardonePatricia J. Lardone
Patricia J. Lardone
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro
AMAlicia Martínez‐López
Alicia Martínez‐López
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico

19 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NÁNuria Álvarez-Sánchez
Nuria Álvarez-Sánchez
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro
MDMaría Díaz-Sánchez
María Díaz-Sánchez
Patricia J. LardonePatricia J. Lardone
Patricia J. Lardone
JGJuan Miguel Guerrero
Juan Miguel Guerrero
Antonio Carrillo-VicoAntonio Carrillo-Vico
Antonio Carrillo-Vico
CD39, an ectonucleotidase that hydrolyses pro-inflammatory ATP, is a marker of highly active and suppressive T regulatory cells (Tregs). Although CD39 has a role in Treg suppression and might be important in the control of neuroinflammation in relapsing-remitting multiple sclerosis (RR-MS), to date, there are contradictory reports concerning the Tregs expression of CD39 in RR-MS patients. Thus, our objectives were to assess the activity and expression of CD39, especially in Tregs from peripheral blood mononuclear cells (PBMCs) of relapsing RR-MS patients compared with control subjects and to evaluate the association of CD39+ Tregs with disability and the odds of RR-MS. The activity and expression of CD39 and the CD39+ Treg frequency were measured in PBMCs from 55 relapsing RR-MS patients (19 untreated and 36 receiving immunomodulatory treatment) and 55 age- and sex-paired controls. Moreover, the association between CD39+ Tregs and RR-MS was assessed by multivariate logistic regression. CD39 activity and the frequency of CD39-expressing Tregs were elevated in relapsing RR-MS patients. Moreover, CD39+ Tregs were significantly correlated with the EDSS score and were independently associated with the odds of RR-MS. Our results highlight the relevance of CD39+ Treg subset in the clinical outcomes of RR-MS.

10 January 2022 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Open access
Ivan Cruz-ChamorroIvan Cruz-Chamorro
Ivan Cruz-Chamorro
Guillermo Santos-SánchezGuillermo Santos-Sánchez
Guillermo Santos-Sánchez
CBCarlotta Bollati
Carlotta Bollati
MBMartina Bartolomei
Martina Bartolomei
JLJianqiang Li
Jianqiang Li
Carmen LammiCarmen Lammi
Carmen Lammi
WVSPLAGRT (H2) and IGFLIIWV (H3) are two transepithelial transported intestinal peptides obtained from the hydrolysis of hempseed protein with pepsin, which exert antioxidant activity in HepG2 cells. Notably, both peptides reduce the H2O2-induced reactive oxygen species, lipid peroxidation, and nitric oxide (NO) production levels in HepG2 cells via the modulation of the nuclear factor erythroid 2-related factor 2 and the inducible nitric oxide synthase (iNOS) pathways, respectively. Due to the close link between inflammation and oxidative stress and with the objective of fostering the multifunctional behavior of bioactive peptides, in this study, the molecular characterization of the anti-inflammatory and immunomodulatory properties of H2 and H3 was carried out in HepG2 cells. In fact, both peptides were shown to modulate the production of pro (IFN-γ: −33.0 ± 6.7% H2, p = 0.011; −13.1 ± 2.0% H3, p = <0.0001; TNF: −17.6 ± 1.7% H2, p = 0.0004; −20.3 ± 1.7% H3, p = <0.0001; and IL-6: −15.1 ± 6.5% H3, p = 0.010)- and anti (IL-10: +9.6 ± 3.1% H2, p = 0.010; +26.0 ± 2.3% H3, p = < 0.0001)-inflammatory cytokines and NO (−9.0 ± 0.7% H2, p = <0.0001; −7.2 ± 1.8% H3, p = <0.0001) through regulation of the NF-κB and iNOS pathways, respectively, in HepG2 cells stimulated by lipopolysaccharides.